Vanessa Carle - Lexaria Bioscience Head Legal

LEXXW Stock  USD 0.88  0.05  6.02%   

Insider

Vanessa Carle is Head Legal of Lexaria Bioscience Corp
Address 740 McCurdy Road, Kelowna, BC, Canada, V1X 2P7
Phone250 765 6424
Webhttps://lexariabioscience.com

Vanessa Carle Latest Insider Activity

Tracking and analyzing the buying and selling activities of Vanessa Carle against Lexaria Bioscience stock is an integral part of due diligence when investing in Lexaria Bioscience. Vanessa Carle insider activity provides valuable insight into whether Lexaria Bioscience is net buyers or sellers over its current business cycle. Note, Lexaria Bioscience insiders must abide by specific rules, including filing SEC forms every time they buy or sell Lexaria Bioscience'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Lexaria Bioscience Management Efficiency

The company has return on total asset (ROA) of (0.3821) % which means that it has lost $0.3821 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.7066) %, meaning that it generated substantial loss on money invested by shareholders. Lexaria Bioscience's management efficiency ratios could be used to measure how well Lexaria Bioscience manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to climb to 0.14 in 2024, despite the fact that Return On Tangible Assets are likely to grow to (0.52). At this time, Lexaria Bioscience's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to climb to about 1.3 M in 2024, despite the fact that Return On Tangible Assets are likely to grow to (0.52).
Lexaria Bioscience Corp has accumulated 137.37 K in total debt with debt to equity ratio (D/E) of 0.06, which may suggest the company is not taking enough advantage from borrowing. Lexaria Bioscience Corp has a current ratio of 8.35, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Note, when we think about Lexaria Bioscience's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Found 14 records

INSIDER Age

CPA CMALexaria Bioscience Corp
63
Christopher BunkaLexaria Bioscience Corp
62
Narayan PrabhuReviva Pharmaceuticals Holdings
52
HansGeorge Rammenseeimmatics biotechnologies GmbH
N/A
Mark NewmanGeoVax Labs
69
Laxminarayan BhatReviva Pharmaceuticals Holdings
59
Marc CantillonReviva Pharmaceuticals Holdings
66
Toni Weinschenkimmatics biotechnologies GmbH
50
Thomas Ulmerimmatics biotechnologies GmbH
N/A
Philip AinslieLexaria Bioscience Corp
N/A
Harpreet Singhimmatics biotechnologies GmbH
49
Harriet RobinsonGeoVax Labs
86
Jessica EdDimmatics biotechnologies GmbH
N/A
CPA CPAGeoVax Labs
62
Lexaria Bioscience Corp. operates in the drug delivery platform business. Lexaria Bioscience Corp. was founded in 2004 and is headquartered in Kelowna, Canada. Lexaria Bioscience is traded on NASDAQ Exchange in the United States. Lexaria Bioscience Corp (LEXXW) is traded on NASDAQ Exchange in USA. It is located in 740 McCurdy Road, Kelowna, BC, Canada, V1X 2P7 and employs 5 people. Lexaria Bioscience is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Lexaria Bioscience Corp Leadership Team

Elected by the shareholders, the Lexaria Bioscience's board of directors comprises two types of representatives: Lexaria Bioscience inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lexaria. The board's role is to monitor Lexaria Bioscience's management team and ensure that shareholders' interests are well served. Lexaria Bioscience's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lexaria Bioscience's outside directors are responsible for providing unbiased perspectives on the board's policies.
Christopher Bunka, Chairman CEO
Vanessa Carle, Head Legal
Philip Ainslie, Advisor Consultant
Nelson CPA, Chief Officer
Richard Christopher, Chief Officer
John MSc, President Director
Michael CPA, Chief Officer
Michael Shankman, Chief Officer
Kristin Hamilton, Director Operations
John Docherty, Pres Director
Mike Shankman, Chief Officer

Lexaria Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Lexaria Bioscience a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Lexaria Stock Analysis

When running Lexaria Bioscience's price analysis, check to measure Lexaria Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexaria Bioscience is operating at the current time. Most of Lexaria Bioscience's value examination focuses on studying past and present price action to predict the probability of Lexaria Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexaria Bioscience's price. Additionally, you may evaluate how the addition of Lexaria Bioscience to your portfolios can decrease your overall portfolio volatility.